3 Things the Smartest Investors Know About This Beaten-Down Stock
Most people consider Moderna (NASDAQ: MRNA) a coronavirus vaccine stock. And for good reason. The vaccine is the company's only product right now. And it's generated billions of dollars in revenue and profit for this biotech player.
Moderna's status as a vaccine stock once brought it major gains. But today, just the opposite is happening. Some investors have dropped Moderna and moved on to other investment themes. But the Moderna story is far from over. And some pretty exciting chapters may lie ahead. Here are three things the smartest investors know about this beaten-down stock.
Moderna expects $21 billion in coronavirus vaccine sales this year. That's according to advance purchase agreements with governments. Moving forward, however, sales figures probably won't be as high. In a post-pandemic world, Moderna expects high-risk individuals -- not the entire population -- to seek vaccination.
Source Fool.com
